ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

CMV Immune Monitoring with a CMV ELISPOT Test in Kidney Transplant Patients.

S. Ball, A. Small, C. Waite.

Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.

Meeting: 2016 American Transplant Congress

Abstract number: 304

Keywords: Cytomeglovirus, Kidney transplantation

Session Information

Date: Monday, June 13, 2016

Session Name: Concurrent Session: CMV: Immune Monitoring & MicroRNA Responses

Session Time: 4:30pm-6:00pm

 Presentation Time: 4:30pm-4:42pm

Location: Room 306

Related Abstracts
  • Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.
  • Urine-Derived Cell Lines as a Novel Tool for Monitoring Allo-Reactivity in Kidney Transplant Patients.

Cytomegalovirus (CMV) is an important opportunistic infection in kidney transplant recipients (KTR). Whilst pre-emptive or prophylactic anti-viral regime reduce CMV complications, drug toxicity and resistance suggest that biomarker led stratification of risk may have value in guiding therapy.

Purpose: of the study was to determine peripheral blood frequency of CMV specific T lymphocytes 3 months post kidney transplantation (KTx) and to correlate this with CMV disease.

Methods: This single centre, prospective, observational study recruited 116 KTR, immunosuppressed with tacrolimus based triple immunosuppression. KTR with CMV serology (Donor (D)+/Recipient (R)-) received 3 months valganciclovir prophylaxis. Investigation and treatment of CMV disease was for clinical indication. CMV specific T cell responses (T-SPOT.CMV ELISPOT, Oxford Diagnostics Laboratories, Abingdon, UK) and viral load on stored samples (Roche LightCycler®) were serially assessed from 3 months post KTx. This analysis categorized a T-SPOT.CMV test result as low if the maximum spot count in either antigen well was <50 spots per 250,000 cells; medium if 50-100; and high if >100.

Results: An interim analysis is reported for 79 KTR with test results available at 3 and 6 months. T-SPOT.CMV response at 3 months varied by sero-status and was medium-high in 49% of patients [D-/R- 16% (4/25); D-/R+ 93% (13/14); D+/R+ 86% (18/21) and D+/R- 21% (4/19)]. In the D+/R- group: none of 4 KTR with a medium-high response at 3 months developed CMV disease whereas 4 of 15 KTR with a low response developed CMV disease and 1 of 15 asymptomatic viremia. Between 3 and 6 months T-SPOT.CMV response increased from low to medium-high in 5 patients (1 D-/R+, 1 D+/R+, 3 D+/R-). All but one of these (D-/R+) sustained a significant episode of viremia although only one (D+/R-) then had CMV disease.

Conclusion: Most R+ recipients (86%) had a medium-high T-SPOT.CMV response at 3 months. The 4 D+/R- KTR with a medium-high response at 3 months post KTx remained free of CMV disease at 6 months post KTx (and remain so to >11 months). Although this study is not powered to comment further, this may be biologically significant and will be addressed in an ongoing larger study. This interim analysis indicates how such tests might guide personalized decisions regarding CMV management such as length of prophylaxis, particularly in the high risk D+/R- group.

CITATION INFORMATION: Ball S, Small A, Waite C. CMV Immune Monitoring with a CMV ELISPOT Test in Kidney Transplant Patients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ball S, Small A, Waite C. CMV Immune Monitoring with a CMV ELISPOT Test in Kidney Transplant Patients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/cmv-immune-monitoring-with-a-cmv-elispot-test-in-kidney-transplant-patients/. Accessed February 28, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.